Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity

@inproceedings{Vo2015DendriticCV,
  title={Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity},
  author={Manh-Cuong Vo and Hyun-ju Lee and Jong-Seok Kim and M Hoang and Nu-Ri Choi and Joon Haeng Rhee and Vinoth-Kumar Lakshmanan and Sung-Jae Shin and Je-Jung Lee},
  booktitle={Oncotarget},
  year={2015}
}
Dendritic cell (DC)-based vaccines are considered useful in cancer immunotherapy, and the interaction of DC and adjuvants is important in the design of the next generation vaccines. In this study, whether DC combined with Rv2299c derived from mycobacteria could improve anti-tumor immune responses in a colon cancer mouse model was evaluated. MC38 cell lines were injected subcutaneously to establish colon-cancer-bearing mice and the following four groups were evaluated: PBS control, tumor antigen… CONTINUE READING
Tweets
This paper has been referenced on Twitter 7 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Similar Papers

Loading similar papers…